INTRODUCTION
============

Although traditional Chinese medicine (TCM) is a prominently recognized branch of complementary and alternative medicine (CAM), it is only one of the many forms of CAM practiced worldwide. Other noteworthy forms of CAM include Ayurveda in India, traditional Mongolian medicine, traditional Vietnamese medicine, and Sasang constitutional medicine in Korea \[[@B1]\]. Sasang typology is a traditional Korean classification system that categorizes people into four constitutional types based on the biopsychosocial characteristics, emphasis of the balance between *Yin* (the feminine passive principle, persistence, wetness, cold, darkness) and *Yang* (the masculine active principle, dryness, heat, and light) such as: Soyangin (SY, "lesser yang"), Soeumin (SE, "lesser yin"), Taeeumin (TE, "greater yin"), and Taeyangin (TY, "greater yang") \[[@B2]\]. Sasang typology was first introduced by Jema Lee at the end of the 19^th^ century in his book, Donguisusebowon ("Longevity and Life Preservation in Eastern Medicine") \[[@B3]\]. Sasang constitution medicine is type of personalized medicine in which the diseases are diagnosed and treated by categorizing patients into one of the four types based on both body composition and psychological factors \[[@B4]\]. Traditional countries such as China, India, and Korea have had a long history of using food as a substitute for medicine, and several studies have reported that certain foods may be beneficial or detrimental based on an individual\'s Sasang constitution \[[@B5][@B6]\]. Furthermore, many Korean individuals turn to herbal and food-based Sasang remedies when modern medicine has fails to improve their health conditions. In a survey of 839 Koreans (55% of men, 45% of women; age range: 20--60 years), 90% of the participants were aware of Sasang typology, and approximately 88% believed that they should follow a diet suitable for their body type for the prevention and treatment of disease \[[@B7]\]. However, most of these beliefs are based on information presented in traditional medical texts, raising questions regarding their scientific validity.

Over the last decade, researchers in various fields have applied scientific approaches to Sasang typology, demonstrating that patients with specific constitutions are susceptible to hypertension \[[@B8]\], diabetes \[[@B9]\], sleep apnea \[[@B10]\], and metabolic disorders \[[@B11][@B12]\]. Additional studies have revealed that, relative to patients with other constitutional types, individuals with the TE constitution exhibit increased body mass, triglycerides, total cholesterol, blood pressure, and risk of metabolic syndrome \[[@B13]\]. Although Sasang typology is primarily concerned with the diagnostic aspects of disease, food intake according to Sasang type is regarded as an important means for preventing the onset and progression of disease. Following pharmacotherapeutic treatment, changes in food intake are often recommended to promote good health in patients with various diseases \[[@B14]\]. Kim et al. \[[@B15]\] reported improvement in the level of cholesterol and triglycerides associated with favorable outcomes in patients with hyperlipidemia after food intake according to Sasang typology. An additional study suggested that patients with the SE constitution are more susceptible to sweating, anemia, and flushing following the ingestion of red ginseng \[[@B16]\]. However, the reported association between the Sasang typology and diet differs across studies, and there is minimal scientific evidence supporting the association between the constitutional type of individual and food. In particular, nutrikinetic studies based on Sasang constitution have not been conducted based on food.

*Cheonggukjang* is a quick-fermented soybean paste used in various Korean foods. Several previous studies have documented the potential health benefits of *cheonggukjang*, including its anti-obesity, anti-oxidant, anti-osteoporotic, and anti-prediabetic effects \[[@B17][@B18][@B19][@B20]\]. Although Sasang typology recommends the ingestion of soybeans for patients with the TE constitution, the scientific evidence in support of this recommendation is minimal. In our previous study, we identified and analyzed the nutrikinetics of individual metabolites of isoflavones, metabolized in the blood following the intake of *Cheonggukjang* in an animal model \[[@B21]\]. In addition, we have reported the difference in metabolomic and lipidomic parameters according to Sasang constitution \[[@B22]\]. In the present study, we aimed to determine whether Sasang constitution is associated with the differences in the bioavailability of soy isoflavones derived from *Cheonggukjang*. Sasang constitution was classified using the questionnaire for Sasang Constitutional Classification II (QSCCII) prepared by doctors practicing Oriental medicine. Isoflavone-derived metabolites in the blood were identified using liquid chromatography-tandem mass spectrometry (LC-MS).

SUBJECTS AND METHODS
====================

Participants and study design
-----------------------------

Previously, we examined whether the metabolomics and lipidomics analysis of human plasma could classify the Sasang constitution types in 48 healthy Korean men between the age of 21 and 29 years \[[@B22]\]. The present study measured the bioavailability of soy isoflavone metabolites in blood after the ingestion of *Cheonggukjang*, in the 48 participants from the previously described study. This human study was approved (KMISC-FD-22) by the Daegu Oriental Hospital of Daegu Hanny University (Daegu, South Korea). The analysis was only performed for three constitutions, i.e., TE, SE, and SY because the TY constitution is very rare. Among the Korean population, 20% of SY, 50% of TE, 30% of SE, and below 0.1% of TY were reported \[[@B23]\]. Participants were classified into the TE (n = 15), SY (n=15), and SE (n=18) groups by an Oriental medicine doctor based on the QSCC II \[[@B24]\], face, body shape, and voice. Details on participant recruitment are described in the previous study \[[@B22]\]. Briefly, individuals with a body mass index (BMI) \< 18.5 kg/m^2^ or \> 30 kg/m^2^, hypertension, ALT/AST more than twice the normal upper limit, those participating in other studies, those who donated blood during the past month, and those with chronic diseases were excluded. Participants fasted for 10--17 h prior to the collection of blood samples. Each participant ingested 50 g of *Cheonggukjang* per 60 kg body weight following which blood was collected in an ethylenediaminetetraacetic acid containing plasma tubes at different time points (0.5 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h). The daily intake of *Cheonggukjang* was determined by referring to the top 10 products of the NAVER (<https://www.naver.com>) search and the average intake was about 50 g. The blood samples were centrifuged at 1,550 × g for 10 min at 4℃. Thereafter, the plasma was separated and stored at −80℃ until analysis. The *Cheonggukjang* used in this study is the same as the one used in our previous work, and comprised \> 90% isoflavone aglycones, such as genistein and daidzein \[[@B21]\].

Sample preparation and LC-MS/MS analysis
----------------------------------------

Plasma proteins were precipitated with cold methanol. After mixing for 30 min at 4℃, the samples were centrifuged at 10,000 rpm for 10 min at 4℃. The supernatant was dissolved in 50% aqueous methanol containing caffeine for ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF) analysis. UPLC-MS analysis was performed using an Acquity UPLC system (Waters, Miliford, MA, USA) coupled to an Waters SYNAPT G2-Sir mass spectrometer (Waters Corp., Manchester, UK). Chromatographic separation of samples was performed on ACQUITY UPLC BEH C18 (2.1 × 100 mm, 1.7 µm) column was used with a column temperature of 40℃ and flow rate of 0.35 mL/min. The mobile phase A constituted water with 10 mM ammonium acetate, and mobile phase B constituted acetonitrile with 0.1% formic acid. The gradient conditions were 0.5% B rising to 70% in 18 min; thereafter, to a maximum of 99.5% after 1 min, and subsequently, equilibrated at 0.5% B for 1min. The auto-sampler was conditioned at 4℃ and the injection volume was set to 5 uL. The Q-TOF-MS was operated in negative electrospray ionization mode, with a scan range of m/z 50--1,000. The cone voltage was 30 V, capillary voltage was 1 kV, and scan time was 0.2s, with an interscan delay of 0.02s. The source temperature was set at 120℃, while the desolvation flow was set to 800 L/h; the desolvation gas temperature was set at 500℃. The MS was calibrated using sodium formate to ensure accuracy, and leucine enkephalin was injected as a lock mass at a concentration of 200 ρM and flow rate of 5 µL/min. The detected values were corrected simultaneously and independently. In the MS-MS experiments, argon was used as the collision gas, with the collision energy alternating between 25 and 45 eV.

Identification of isoflavone metabolites
----------------------------------------

UNIFI software (ver. 1.7.1, Waters, Manchester, UK) was used for LC-MS/MS data collection, data mining, and library searching. After detecting the peak of a complex matrix, a componentization process was performed to create a single spectrum representing the peak, and to organize the unrelated spectra. Spectrum- and structure-matching were performed to identify the metabolites after obtaining information on the MS value, adduct, and high and low energy components with a specific retention time. In the quantitative analysis of isoflavone metabolites, the height of each peak was used to measure the intensity. Analytical validation was based on the exact mass and retention time of standard compounds.

Genistein (G6776), daidzein (16587), and glycitein (G2785) were purchased from Sigma-Aldrich (St Louis, MO, USA). Daidzein 4′-glucuronide (D103490), daidzein 7-glucuronide (D103510), daidzein 4′-sulfate (D103520), genistein 7-glucuronide (G350015), genistein diglucuronide (G350055), genistein 4′-sulfate (G350045), daidzein 7-sulfate 4′-glucuronide (D103565), daidzein diglucuronide (D103575), genistein 7-glucuronide-4′-sulfate (G350050), and genistein 7-sulfate (G350045) were purchased from Toronto Research Chemicals (Toronto, Ontario, Canada). Dihydrogenistein (sc-498873), equol 7-glucuronide (sc-219699), and equol 4′-sulfate (sc-219698) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). *O*-desmethylangolensin (ODMA) was purchased from Plantech UK (Reading, Berkshire, UK). 2-hydroxygenistein (GFN99257) was purchased from ChemFaces (Wuhan, China). 3-hydroxydaidzein (1309) was purchased from Extrasynthese (Geray, France). Dihydrodaidzein sulfate and 5-hydroxyequol were identified putatively based on accurate mass and MS/MS fragments.

Nutrikinetic analyses
---------------------

Nutrikinetic analyses for each isoflavone-derived metabolite collected from individual subjects was performed using noncompartmental methods and nutrikinetic parameters, including the maximum peak area (PA) (*C*~max~), time to reach *C*~max~ (*T*~max~), terminal elimination half-time (*t*~1/2~), and the area under the curve of the metabolite peak area versus time (AUC~0-24\ h~) were calculated using PK solutions ver. 2.0 (Summit Research Services, Montrose, CO, USA) \[[@B21]\].

Statistical analysis
--------------------

All data (*C*~max~, *T*~max~, t~1/2~, and AUC) are expressed as mean ± SEM, and analyzed using one-way analyses of variance (ANOVA) followed by comparison of Duncan\' multiple post-hoc analysis. Differences among groups were considered statistically significant at *P* \< 0.05 and are indicated by different lowercase letters. All statistical analyses were analyzed using SPSS ver. 20 (IBM, Armonk, New York, United States).

RESULTS
=======

Identification of isoflavone metabolites
----------------------------------------

The levels of isoflavone metabolites in the participants\' blood samples after the ingestion of *Cheonggukjang* were analyzed by UPLC-QTOF-MS. A total of 21 isoflavone metabolites were identified based on retention time, molecular weight, and fragment ions when compared to authenticated standards ([Table 1](#T1){ref-type="table"}) such as: intact isoflavone (n = 3), phase I metabolites (n = 2), phase II metabolites (n = 10), and gut-mediated metabolites (n = 6).

Nutrikinetic analysis of isoflavone metabolites according to sasang constitution
--------------------------------------------------------------------------------

Significant differences (*P* \< 0.05) in the time to reach maximum concentration (*T*~max~) were observed among the SE, SY, and TE groups for nine isoflavone metabolites ([Table 2](#T2){ref-type="table"}). The high *T*~max~ (h) values for the metabolites were observed in the SE group compared to the SY and TE groups. In addition, the fastest rate of metabolite decay was observed in the TE group, with the exception of those for genistein 7-glucuronide-4′-sulfate and equol-7-glucuronide. Significant differences in the maximum metabolite concentrations (*C*~max~) of 15 metabolites were observed among the three groups ([Table 3](#T3){ref-type="table"}). Notably, the mean *C*~max~ of intact isoflavones in the TE group was 21 times higher than that in the SE group and 7.7 times higher than that in the SY group. The *C*~max~ values of most isoflavone metabolites were significantly lower (*P* \< 0.05) in the SY group than in the remaining two groups. The area under the plasma level-time curve (AUC~0-24\ h~) represents the total amount of active drug that reaches the systemic circulation, reflecting the bioavailability of the drug. The AUC~(0-24\ h)~ values for intact isoflavones were 5.3 and 0.4 times higher in the TE group than in the SY and SE groups, respectively ([Table 4](#T4){ref-type="table"}). AUC~(0-24\ h)~ values for phase I metabolites were significantly higher (*P* \< 0.05) in the TE and SE groups than in the SY group. In contrast, the AUC values for phase II metabolites were 2.7 and 6.4 times higher in the TE group than in the SY and SE groups, respectively. In particular, daidzein 4-sulfate was the most representative phase II metabolite in the TE group. The AUC~(0-24\ h)~ of genistein-derived metabolites were found to be relatively high in the SE group. Equol-7-glucuronide was detected in all three groups, while equol-4-sulfate was detected only in the TE group. The levels of equol metabolites were lower in the SY group than in the TE and SE groups.

DISCUSSION
==========

In our previous study, we investigated the probable classification of Sasang constitution through metabolomics and lipidomics analysis from human blood, and have proposed several candidate metabolites representative of the Sasang constitution \[[@B22]\]. In this study, we aimed to investigate the change in the bioavailability of functional ingredients after the ingestion of food according to Sasang typology. To validate this hypothesis, we investigated the differences in the bioavailability of soy isoflavones after the intake of *Cheonggukjang* in the same cohort of participants used in the previous study. The participants in the present study exhibited significant differences among the three groups for body mass index (BMI), body fat percentage (BFP), waist-to-hip ratio (WHR), and systolic blood pressure (SBP) \[[@B22]\]. Especially, the BMI, BFP, VFA, and SBP were higher in the TE and SY groups than in the SE group. In Sasang typology, individual with the SE constitution were found to be thinner than those in the SY and TE groups \[[@B1]\].

Sasang typology is not only used for the treatment of diseases but also for their prevention, since a specific diet is often recommended to each patient based on his or her constitutional type. Studies have been conducted on the treatment or prevention of diseases using a variety of diets to determine the correlation between diet and Sasang constitution \[[@B25]\]. Most dietary studies concerning Sasang constitution have investigated its relationship with diseases; however, no studies have attempted to identify the association of the bioavailability of functional ingredients according to Sasang typology. Nutrikinetics analyses are required to determine the differential mechanism, absorption, distribution, and excretion of same functional groups from the same food function in patients with different constitutions. Our recent *in vivo* studies have demonstrated that the bioavailability of functional ingredients following the ingestion of the same food may differ depending on health conditions, even when the food is ingested in the same form \[[@B21][@B26]\]. Therefore, the bioavailability of functional ingredients of food are important in the treatment or prevention of diseases \[[@B27]\].

*Cheonggukjang* is one of the most commonly consumed fermented soybean pastes in Korea, and soy isoflavones and saponins are its well-known functional ingredients \[[@B28]\]. In Sasang constitutional medicine, soybean and soybean products including *Cheonggukjang*, is considered more suitable for individuals with the TE constitution, as it is thought to eliminate moisture from the body, improve circulation, and enhance healing \[[@B29]\]. In the present study, the AUC-indicated bioavailability of intact isoflavones (genistein, daidzein, and glycitein) and total metabolites was significantly higher in the TE group than in the SY and EY groups ([Fig. 1](#F1){ref-type="fig"}). The increased bioavailability of *Cheonggukjang* isoflavones may contribute to health improvement in individuals with the TE constitution. In addition, the levels of equol metabolites were lower in the SY group than in the SE and TE groups. Equol is one of the metabolites produced by the bacteria present in the intestinal tract of subjects ingesting soy-containing isoflavones \[[@B30]\]. It is also worth considering if the observed effect was mediated by Sasang constitution on intestinal microbial environment. High isoflavone bioavailability may indicate that isoflavones exhibit greater efficacy in individuals with the TE constitution. Although the bioavailability of isoflavones, as determined by nutrikinetic analyses is insufficient to adequately characterize patients into different constitutional types, the analyses of bioavailability may help explain the association between Sasang constitution and diet.

There are some limitations to this study. First, the participant cohort was small and unsuitable for validating the association between diet and Sasang constitution-based system of classification. Therefore, current evidence on the bioavailability of isoflavones in *Cheonggukjang* is limited. Second, the objective nature and scientific reproducibility of the Sasang constitution is controversial. Third, additional evidence is needed to ascertain if Sasang constitution can be used as a measure for assessing the bioavailability and constitution of dietary isoflavones observed in plasma after the ingestion of *Cheonggukjang*.

In conclusion, our results indicate that the overall bioavailability of isoflavone metabolites, after the ingestion of *Cheonggukjang*, was higher in the TE group than in the other two groups. Data on the bioavailability of functional ingredients according to Sasang typology might be useful for recommending appropriate diet for the prevention of disease, emphasizing on the functional aspects of oriental medicine.
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![Overview of *T*~max~ (h), *t*~1/2~ (h), *C*~max~, and AUC~(0-24\ h)~ for 21 isoflavone metabolites detected in the plasma following ingestion of *Cheonggukjang* according to sasang typology.\
Error bars represent the mean ± SEM (^\*^ *P* \< 0.05; ^\*\*^ *P* \< 0.01; ^\*\*\*^ *P* \< 0.001). SE, *Soeumin*; SY, *Soyangin*; TE, *Taeeumin*; AUC~(0-24\ h)~: area under the curve of the metabolite peak area versus time; *T*~max~, time to maximum concentration; *t*~1/2~, elimination half-life; *C*~max~, maximum peak area.](nrp-14-102-g001){#F1}

###### Isoflavone metabolites identified in the plasma following *Cheonggukjang* ingestion

![](nrp-14-102-i001)

  No   Metabolites                Exact mass (m/z)                     Actual mass (m/z)   Mass error (mDa)   RT (min)   MS fragments   
  ---- -------------------------- ------------------------------------ ------------------- ------------------ ---------- -------------- --------------------
  1    Intact isoflavones         Daidzein                             253.0501            253.0499           -2.20      7.44           195
  2                               Genistein                            269.045             269.0455           0.5        8.80           224, 201, 183
  3                               Glycitein                            283.0606            283.0613           0.7        6.46           269, 266, 240
  4    Phase I metabolites        3-hydroxydaidzein                    269.045             269.0473           2.3        5.26           253
  5                               2-hydroxygenistein                   285.0399            285.0425           -1.55      8.17           269
  6    Phase II metabolites       Daidzein 4′-glucuronide              429.0822            429.0894           7.2        3.85           253
  7                               Daidzein 7-glucuronide               429.0822            429.0826           0.4        5.02           253
  8                               Daidzein diglucuronide               605.1143            605.1157           1.4        2.85           429, 253
  9                               Daidzein 4′-sulfate                  333.0069            333.0071           0.2        6.34           253
  10                              Daidzein 7-sulfate 4′-glucuronide    509.039             509.0398           0.8        4.55           253
  11                              Genistein-7-glucuronide              445.0771            445.0790           1.9        5.92           300, 269, 206,134
  12                              Genistein diglucuronide              621.1092            621.1094           0.24       2.93           445, 269
  13                              Genistein 7-glucuronide 4′-sulfate   525.0339            525.0346           0.7        4.53           349, 269, 224, 133
  14                              Genistein 4′-sulfate                 349.0018            349.0023           0.48       6.6            269, 224, 133
  15                              Genistein 7-sulfate                  349.0018            349.0019           0.1        7.48           349, 269
  16   Gut-mediated metabolites   Dihydrogenistein                     271.0606            271.0600           -0.6       8.82           165
  17                              Dihydrodaidzein sulfate              335.0225            335.0237           1.2        6.50           253
  18                              Equol-7-glucuronide                  417.1186            417.1180           -0.6       5.52           241, 175, 113
  19                              Equol-4′-sulfate                     321.0433            321.0420           -1.31      7.24           241, 135, 119
  20                              5-hydroxy equol                      257.0814            257.0459           2.6        7.44           257, 151, 105
  21                              O-Desmethylangolensin                257.0814            257.0866           5.2        9.64           257

MS, mass spectrometry; RT, retention time; m/z, mass/charge.

###### *T*~max~ and *t*~1/2~ of isoflavone metabolites identified in the plasma following *Cheonggukjang* ingestion according to Sasang typology.

![](nrp-14-102-i002)

  No   Isoflavone metabolites               *T*~max~ (h)      *t*~1/2~ (h)                                                                                       
  ---- ------------------------------------ ----------------- ----------------- ---------------- ------- ----------------- ------------------ ------------------ -------
  1    Daidzein                             1.35 ± 0.76^b^    1.13 ± 0.34^ab^   0.73 ± 0.40^a^   0.012   5.8 ± 3.59        4.03 ± 2.35        4.45 ± 2.58        0.246
  2    Genistein                            2.5 ± 2.52        2.33 ± 3.19       0.8 ± 0.87       0.121   10.15 ± 7.3       8.03 ± 6.93        9.76 ± 6.15        0.714
  3    Glycitein                            2 ± 2.54^b^       1.07 ± 0.25^ab^   0.53 ± 0.12^a^   0.038   10.92 ± 5.49^b^   11.26 ± 6.33^b^    6.19 ± 3.37a       0.029
  4    3-hydroxydaidzein                    3.66 ± 2.57       8 ± 2.83          7.14 ± 7.32      0.356   5.48 ± 1.87^b^    0.92 ± 0.59^a^     0.92 ± 1.37a       0.000
  5    2-hydroxygenistein                   9.14 ± 6.41^b^    2.6 ± 3.74^a^     2.57 ± 3.81^a^   0.000   18.95 ± 15.91     16.08 ± 14.76      26.0 ± 31.95       0.576
  6    Daidzein 4′-glucuronide              2.11 ± 2.21       1.07 ± 0.25       2.27 ± 2.06      0.159   5.67 ± 4.95       3.51 ± 2.64        7.39 ± 8.57        0.225
  7    Daidzein 7-glucuronide               3.89 ± 3.03^b^    1.2 ± 0.4^a^      2.5 ± 1.82^ab^   0.004   4.51 ± 4.59       4.90 ± 2.85        3.27 ± 4.65        0.564
  8    Daidzein diglucuronide               2.89 ± 0.99       2.43 ± 0.82       2.27 ± 0.68      0.118   1.87 ± 1.34^b^    1.40 ± 1.14^b^     0.46 ± 0.26^a^     0.002
  9    Daidzein 4′-sulfate                  1.5 ± 0.5^b^      1 ± 0^a^          0.83 ± 0.39^a^   0.000   4.76 ± 3.2        4.95 ± 3.03        4.59 ± 2.67        0.951
  10   Daidzein 7-sulfate 4′-glucuronide    10.83 ± 5.68^b^   9 ± 7.07^b^       3.23 ± 3.57^a^   0.002   2.99 ± 1.42^ab^   5.89 ± 4.98^b^     2.49 ± 4.31^a^     0.060
  11   Genistein 7-glucuronide              1.61 ± 0.49       1.67 ± 1.74       2.07 ± 2.37      0.724   5.98 ± 5.04^b^    3.99 ± 4.30^ab^    1.91 ± 2.29^a^     0.045
  12   Genistein diglucuronide              5.67 ± 2.52^b^    4.29 ± 2.91^ab^   3.6 ± 1.96^a^    0.072   8.1 ± 2.39^ab^    8.95 ± 5.12^b^     6.07 ± 1.96^a^     0.083
  13   Genistein-7-glucuronide-4′-sulfate   5.67 ± 3.77^b^    5.71 ± 4.27^b^    1.77 ± 1.01^a^   0.003   4.05 ± 3.7^ab^    1.99 ± 3.27^a^     11.58 ± 17.32^b^   0.061
  14   Genistein 4′-sulfate                 5.47 ± 6.2        1.53 ± 0.5^\*^    \-               0.024   6.69 ± 8.01       13.65 ± 5.28^\*^   \-                 0.017
  15   Genistein-7-sulfate                  \-                \-                1.03 ± 0.53      0.000   \-                \-                 5.48 ± 4.5         0.000
  16   Dihydrogenistein                     15.18 ± 7.97      13.46 ± 7.44      11.1 ± 8.95      0.401   7.57 ± 5.72       3.61 ± 3.40        9.56 ± 8.79        0.127
  17   Dihydrodaidzein sulfate              11.86 ± 8.95      9.67 ± 1.97       9.33 ± 5.35      0.539   24.39 ± 8.63^b^   4.53 ± 2.44^a^     4.37 ± 2.86^a^     0.000
  18   Equol-7-glucuronide                  16.33 ± 6.62^b^   9 ± 8.92^a^       7.92 ± 6.26^a^   0.020   6.32 ± 1.46^a^    19.15 ± 12.66^b^   6.16 ± 8.22^a^     0.010
  19   Equol-4-sulfate                      \-                \-                5.33 ± 3.59      0.000   \-                \-                 0.52 ± 0.32        0.000
  20   5-hydroxy equol                      11.5 ± 5.07       4.8 ± 3.71        11.61 ± 7.32     0.137   2.17 ± 0.87       0.73 ± 0.36        1.78 ± 1.31        0.153
  21   *O*-Desmethylangolensin              11.11 ± 3.66      7.81 ± 6.38       10.27 ± 2.82     0.140   4.81 ± 5.11       3.32 ± 3.15        4.36 ± 3.69        0.665

SE, *Soeumin*; SY, *Soyangin*; TE, *Taeeumin*; *T*~max~, time to maximum concentration; *t*~1/2~, elimination half-life; -, cannot be calculated.

Differences among the groups were analyzed by Duncan\'s multiple range test (*P* \< 0.05) and are indicated by different lowercase letters.

Letter "a" is significant to "b", but "ab" is not significant.

###### *C*~max~ of isoflavone metabolites identified in the serum following Cheonggukjang ingestion according to Sasang typology.

![](nrp-14-102-i003)

  No   Metabolites                          SE                      SY                        TE                         *P*-value
  ---- ------------------------------------ ----------------------- ------------------------- -------------------------- -----------
  1    Daidzein                             7,791.4 ± 2,319.2^a^    6,024.4 ± 2,337.6^a^      212,365.8 ± 105,648.9^b^   0.000
  2    Genistein                            3,049.1 ± 1,154.6^a^    30,845.2 ± 24,189.8^b^    91,486.0 ± 40,030.0^c^     0.000
  3    Glycitein                            4,023.1 ± 1,207.3^a^    4,022.0 ± 634.3^a^        9,698.0 ± 2,747.5^b^       0.000
  4    3-hydroxydaidzein                    5,557.2 ± 3,134.4       1,265.8 ± 833.0           5,130.5 ± 6,759.7          0.197
  5    2-hydroxygenistein                   8,083.9 ± 7,713.2^b^    3,372.8 ± 1,227.1^a^      8,782.5 ± 6,066.0^b^       0.034
  6    Daidzein 4′-glucuronide              8,602.4 ± 2,767.0^b^    4,904 ± 1,261.5^a^        7,787.8 ± 1,863.5^b^       0.000
  7    Daidzein 7-glucuronide               9,488.5 ± 3,506.4^b^    6,606.1 ± 1,570.6^a^      8,003.2 ± 1,835.9^ab^      0.011
  8    Daidzein diglucuronide               2,612.1 ± 654.4^b^      1,312.9 ± 326.0^a^        2,819.7 ± 2,767.2^b^       0.033
  9    Daidzein 4′-sulfate                  4,269.3 ± 1,481.3^a^    2,12315.8 ± 57,165.3^b^   715,000.9 ± 179,329.6^c^   0.000
  10   Daidzein 7-sulfate 4′-glucuronide    1,807.3 ± 861.1         1,802.0 ± 476.0           2,312.6 ± 661.0            0.088
  11   Genistein 7-glucuronide              9,830.3 ± 2,876.4^b^    7,452.9 ± 1,717.9^a^      8,344.0 ± 2,033.2^ab^      0.021
  12   Genistein diglucuronide              7,298.4 ± 4,149.6^b^    2,913.6 ± 1,157.0^a^      2,848.8 ± 653.9^a^         0.000
  13   Genistein-7-glucuronide-4′-sulfate   12,963.1 ± 8,084.3^b^   3,803.8 ± 3,398.6^a^      6,833.1 ± 2,075.4^a^       0.000
  14   Genistein 4′-sulfate                 11,294.5 ± 14,782.8     9,518.8 ± 2,631.0         \-                         0.659
  15   Genistein- 7-sulfate                 \-                      \-                        126,029.3 ± 100,712.1      0.000
  16   Dihydrogenistein                     3,436.8 ± 3,261.7       12,123.7 ± 21,125.4       7,928.6 ± 13,903.9         0.290
  17   Dihydrodaidzein sulfate              804.1 ± 488.7^a^        24,384.5 ± 15,160.6^a^    94,131.3 ± 72,667.6^b^     0.000
  18   Equol-7-glucuronide                  9,534.7 ± 7,255.4^b^    468.3 ± 256.9^a^          3,553.9 ± 3,938.9^a^       0.000
  19   Equol-4-sulfate                      \-                      \-                        5,692.0 ± 3,434.8          0.000
  20   5-hydroxy equol                      2,537.7 ± 1,854.1       1,351.2 ± 584.0           1,900.0 ± 1,741.7          0.482
  21   *O*-Desmethylangolensin              3,206.8 ± 2,665.2^b^    1,181.2 ± 669.1^a^        2,803.0 ± 1,426.5^b^       0.019

SE, *Soeumin*; SY, *Soyangin*; TE, *Taeeumin*; *C*~max~, maximum peak area; -, cannot be calculated.

Differences among the groups were analyzed by Duncan\'s multiple range test (*P* \< 0.05) and are indicated by different lowercase letters.

Letter "a" is significant to "b" and "c", but "ab" is not significant.

###### AUC~(0-24\ h)~ of isoflavone metabolites identified in the serum following Cheonggukjang ingestion according to Sasang typology.

![](nrp-14-102-i004)

  No   Metabolites                          SE                           SY                           TE                               *P*-value
  ---- ------------------------------------ ---------------------------- ---------------------------- -------------------------------- -----------
  1    Daidzein                             56,399 ± 18,774.20^a^        29,480.4 ± 11,280.24^a^      748,491.8 ± 282,494.31^b^        0.000
  2    Genistein                            19,846.56 ± 8,312.65^a^      143,137.6 ± 67,995.08^b^     298,415.4 ± 116,138.76^c^        0.000
  3    Glycitein                            41,912.94 ± 11,314.79^a^     37,019.47 ± 7,346.46^a^      69,566.33 ± 23,136.25^b^         0.000
  4    3-hydroxydaidzein                    20,177 ± 8,951.96            7,286.25 ± 2,772.5           22,049.67 ± 30,174.84            0.349
  5    2-hydroxygenistein                   116,443.47 ± 108,650.35^b^   36,360.2 ± 12,293.57^a^      82,759.93 ± 63,820.57^ab^        0.020
  6    Daidzein 4′-glucuronide              59,741.29 ± 17,786.70^b^     30,414.13 ± 7,265.75^a^      50,585 ± 14,090.84^b^            0.000
  7    Daidzein 7-glucuronide               80,745.78 ± 29,501.35^b^     50,427.4 ± 11,690.16^a^      57,662.07 ± 24,969.74^a^         0.002
  8    Daidzein diglucuronide               20,737.39 ± 6,555.99^b^      11,543 ± 4,877.33^a^         9,518.27 ± 3,777.76^a^           0.000
  9    Daidzein 4′-sulfate                  23,419.39 ± 7,387.22^a^      974,579.67 ± 340,431.08^b^   3,244,240.93 ± 1,063,972.11^c^   0.000
  10   Daidzein 7-sulfate 4′-glucuronide    14,362.5 ± 8,030.20^a^       24,555.67 ± 6,302.61^b^      20,541.47 ± 9,702.07^b^          0.004
  11   Genistein 7-glucuronide              64,426.39 ± 34,285.58        46,780.2 ± 21,151.31         43,054.73 ± 24,714.20            0.081
  12   Genistein diglucuronide              82,762.56 ± 26,491.63^b^     34,285.87 ± 15,499.38^a^     34,636.87 ± 5,952.47^a^          0.000
  13   Genistein-7-glucuronide-4′-sulfate   121,239.39 ± 88,332.07^b^    35,797.64 ± 27,104.94^a^     46,511.2 ± 13,365.33^a^          0.000
  14   Genistein 4′-sulfate                 78,567.89 ± 138,035.16       82,584.8 ± 21,945.13         \-                               0.000
  15   Genistein-7-sulfate                  \-                           \-                           243,616.87 ± 133,245.66          0.000
  16   Dihydrogenistein                     37,918.76 ± 34,160.86        85,911.36 ± 191,426.6        35,885.33 ± 25,312.26            0.404
  17   Dihydrodaidzein sulfate              11,347.2 ± 7,347.72^a^       230,100.3 ± 139,539.94^a^    971,317.79 ± 640,145.02^b^       0.000
  18   Equol-7-glucuronide                  101,393.3 ± 67,588.67^b^     6,555.06 ± 3,139.22^a^       43,767.85 ± 62,165.99^a^         0.001
  19   Equol-4-sulfate                      \-                           \-                           35,441.67 ± 46,701.94            0.000
  20   5-hydroxy equol                      22,188.88 ± 31,641.4         8,758.6 ± 4,929.73           20,178.89 ± 17,117.64            0.593
  21   *O*-Desmethylangolensin              33,917.38 ± 26,354.99^b^     13,765.62 ± 7,491.53^a^      30,201.8 ± 14,449.10^b^          0.019

SE, *Soeumin*; SY, *Soyangin*; TE, *Taeeumin*; AUC~(0-24\ h)~, area under the curve of the metabolite peak area versus time; -, cannot be calculated.

Differences among the groups were analyzed by Duncan\'s multiple range test (*P* \< 0.05) and are indicated by different lowercase letters.

Letter "a" is significant to "b" and "c", but "ab" is not significant.
